相关实验视频

Updated: May 10, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在EGFR野生型肺腺癌中,MTHFD2标志着pemetrexed耐药性

Sha Yao¹, Omar Elakad², Xiang Hui Yang³

¹Department of Pathology, The 3rd Xiangya Hospital, Central South University, Changsha, 410013, China.

Discover oncology

|April 20, 2025

概括

MTHFD2基因放大与肺癌的预后不佳有关. 这项研究表明,MTHFD2驱动肺癌细胞增殖和化学抵抗,这表明它是治疗结果的潜在生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

肺癌是全球癌症死亡的主要原因之一.
MTHFD2基因的放大与肺癌患者的预后不佳有关.
通过ERK信号传递,MTHFD2信号影响癌细胞迁移,转移和扩散,但其在化学抵抗中的作用尚不清楚.

研究的目的:

调查MTHFD2在非小细胞肺癌 (NSCLC) 化学抵抗中的作用.
评估MTHFD2表达作为肺腺癌 (LUAD) 的预后生物标志物.
探索MTHFD2,ERK信号传递和EGFR野生型NSCLC中对pemetrexed的耐药性之间的关系.

主要方法:

免疫组织化学和下一代测序 (NGS) 用于分析79个NSCLC样本中的MTHFD2表达和EGFR状态.
在两个具有野生型EGFR的NSCLC细胞系 (HCC44和H1993) 中进行了MTHFD2基因敲除.
在MTHFD2-操纵细胞系中评估了ERK信号传递和对pemetrexed的化学抵抗.

主要成果:

MTHFD2表达与LUAD的预后有很强的相关性.
在HCC44细胞中,MTHFD2倒置诱导细胞循环停止,但不是细胞亡.
MTHFD2的表达促进了NSCLC细胞的增殖和对pemetrexed的耐药性,特别是在EGFR野生类型细胞中,由ERK信号介导.

结论:

MTHFD2是LUAD中显著的预后生物标志物,与EGFR野生型瘤的增多和pemetrexed耐药性有关.
针对MTHFD2可能为LUAD患者提供治疗策略.
需要进一步的研究来阐明临床含义和潜在的组合疗法,包括LUAD中MTHFD2.

关键词:

化学抗药性化学抗药性是一种抗药性.欧洲农业基金会 (EGFR) 是一个基金.肺部腺癌瘤是肺部腺癌.在MTHFD2中使用.佩梅特雷克塞德 (Pemetrexed) 是一种

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...